Elevation Oncology, Inc. (ELEV) is gearing up to report data from its phase 1 study to treat patients with advanced solid tumors, using its drug EO-3021, in mid-Q3 of 2024. This will be a major ...
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results